BRAF V600E Mutation Has Variable Tumor-Specific Effects on Expression of MAPK Pathway Genes That Could Affect Patient Outcome
International Journal of Molecular Sciences · 16.08.2025 · 26 (16) · 7910
DOI: 10.3390/ijms26167910 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 16.08.2025. Verfasst von Sourat Darabi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Hoag Family Cancer Institute, Newport Beach, CA 92663, USA. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins B-raf, Melanoma, Mutation, Thyroid Neoplasms. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
BRAF inhibitors have a 50–70% response rate in melanoma but are less effective for thyroid cancer. Differential response may be from activation or expression of downstream mitogen-activated protein kinase (MAPK) pathway genes. Retrospective analysis compared whole exome and transcriptome sequencing in melanoma and thyroid cancers from April 2019 to October 2023. The MAPK Activation Score (MPAS) was calculated using Z-score normalized/log-transformed values indicating expression across 10 MAPK-associated genes. Our tumor registry provided outcome data. BRAF V600E mutations were identified in 33 of 200 (17%) melanomas and 14 (7%) had other BRAF mutations (V600K/R). Of 49 thyroid tumor samples, BRAF V600E mutations were found in 19 (39%). RNA expression of BRAF and the 10 MAPK-associated genes were increased in melanomas with V600E compared to wild-type BRAF (p = 0.02). Conversely, BRAF V600E mutation in thyroid cancer was not associated with increased expression nor MAPK pathway activation. No significant difference in overall survival based on BRAF mutation was observed in the subset of patients where data was available. The MAPK pathway is differentially affected by the different cancers, with increased MAPK activation observed in melanoma and not in thyroid cancer. This may account in part for the observed differential response to BRAF inhibitors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hoag Family Cancer Institute, Newport Beach, CA 92663, USA.
- School of Life Sciences, Arizona State University, Tempe, AZ 85287, USA.
- Fulgent Genetics, El Monte, CA 91731, USA.
- Translational Genomics Research Institute, Phoenix, AZ 85004, USA.
ORCID-Profile: Sourat Darabi, Phillip Stafford, Carlos E Zuazo
Zitieren
APA
Darabi, S., Stafford, P., Braxton, D. R., Zuazo, C. E., Brodie, T. J., & Demeure, M. J. (2025). BRAF V600E Mutation Has Variable Tumor-Specific Effects on Expression of MAPK Pathway Genes That Could Affect Patient Outcome. International Journal of Molecular Sciences, 26(16), 7910. https://doi.org/10.3390/ijms26167910
Vancouver
Darabi S, Stafford P, Braxton DR, Zuazo CE, Brodie TJ, Demeure MJ. BRAF V600E Mutation Has Variable Tumor-Specific Effects on Expression of MAPK Pathway Genes That Could Affect Patient Outcome. International Journal of Molecular Sciences. 2025;26(16):7910. doi:10.3390/ijms26167910
BibTeX
@article{Darabi2025,
author = {Darabi, Sourat and Stafford, Phillip and Braxton, David R and Zuazo, Carlos E and Brodie, Taylor J and Demeure, Michael J},
title = {BRAF V600E Mutation Has Variable Tumor-Specific Effects on Expression of MAPK Pathway Genes That Could Affect Patient Outcome},
journal = {International Journal of Molecular Sciences},
year = {2025},
volume = {26},
number = {16},
pages = {7910},
doi = {10.3390/ijms26167910}
}
EUVIMED